Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy in End-Stage Renal Disease (ESRD) Subjects With Hyperphosphatemia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy in End-Stage Renal Disease (ESRD) Subjects With Hyperphosphatemia

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenapanor (Primary) ; Phosphate binding modulators
  • Indications Hyperphosphataemia
  • Focus Registrational; Therapeutic Use
  • Acronyms AMPLIFY
  • Sponsors Ardelyx
  • Most Recent Events

    • 06 Nov 2019 According to an Aldelyx media release, data will be presented at Kidney Week 2019, the American Society of Nephrology's Annual Meeting.
    • 12 Sep 2019 Status changed from active, no longer recruiting to completed, according to an Ardelyx media release.
    • 03 Sep 2019 Primary endpoint has been met. (Change in serum phosphorus (s-P) level from baseline and at Week 4. [ Time Frame: 4 Weeks (28 days randomization period) ]), according to an Ardelyx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top